Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
January 03 2024 - 8:30AM
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical
biopharmaceutical company focused on the discovery, development and
commercialization of drugs for the treatment of cancer, today
announced it will host a call detailing top-line data from its
pivotal trial of iopofosine I 131 in Waldenstrom’s
macroglobulinemia on Monday, January 8, 2024 at 8:00 am ET.
The company will also be presenting at the Biotech Showcase
conference the following day. Details for each event are as
follows:
Top-line Conference call details: |
Date: |
Monday, January 8, 2024 |
Time: |
8:00 am ET / 5:00 am PT |
Dial-in: |
1-888-886-7786 |
Webcast Link: |
Click HERE |
Biotech Showcase Presentation |
Date: |
Tuesday, January 9, 2024 |
Time: |
5:00 pm ET / 2:00 pm PT |
Location: |
Hilton San Francisco Union Square |
Webcast: |
Click HERE |
A replay of both the conference call and Biotech Showcase
presentation will be available on the investor’s portion of the
company’s website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the
discovery and development of drugs for the treatment of cancer. The
company is developing proprietary drugs independently and through
research and development collaborations. The company’s core
objective is to leverage its proprietary Phospholipid Drug
ConjugateTM (PDC) delivery platform to develop PDCs that
specifically target cancer cells to deliver improved efficacy and
better safety with fewer off-target effects. The company’s PDC
platform possesses the potential for the discovery and development
of the next generation of cancer-targeting treatments and develops
PDCs independently and through research and development
collaborations.
The company’s product pipeline includes
iopofosine I 131, a small-molecule PDC designed to provide targeted
delivery of iodine-131 (radioisotope), proprietary preclinical PDC
chemotherapeutic programs, and multiple partnered PDC assets. The
company is currently investigating iopofosine in a global,
open-label, pivotal expansion cohort in relapsed or refractory WM
patients who have received at least two prior lines of therapy,
including those who have failed or had a suboptimal response to
Bruton tyrosine kinase inhibitors. The WM cohort is designed to
evaluate the efficacy and safety of iopofosine for marketing
approval. The company is also evaluating iopofosine in highly
refractory multiple myeloma patients in its Phase 2 CLOVER-1 study
and relapsed/refractory pediatric cancer patients with brain tumors
in the Phase 1 CLOVER-2 study.
The Phase 1 pediatric study is an open-label,
dose-finding study to evaluate the activity and safety of different
dosages and dosing regimens of iopofosine in children and
adolescents with relapsed or refractory brain tumors. The study is
being conducted in up to fifteen leading pediatric cancer centers
in North America.
The company has established exclusivity on a
broad U.S. and international intellectual property rights portfolio
around its proprietary cancer-targeting PLE technology platform,
including iopofosine and its PDC programs.
In addition to the company’s exclusivity to
iopofosine and its phospholipid ethers conjugated to small
molecules, peptides, and oligos, the company now has non-exclusive
rights to the use of the phospholipid ether platform when
conjugating with a chelator to bind select metal radioisotopes.
For more information, please visit
www.cellectar.com and www.wmclinicaltrial.com or join the
conversation by liking and following us on the company’s social
media channels: Twitter, LinkedIn, and Facebook.
MEDIA:Clair LaCagninaBliss Bio
Health315-765-1462clacagnina@blissbiohealth.com
INVESTORS:Chad KoleanChief Financial
Officerinvestors@cellectar.com
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2023 to Apr 2024